In the News

SGLT2 inhibitors may protect against some major cardiovascular events

Sodium-glucose cotransporter-2 (SGLT2) inhibitors were associated with lower risk of major adverse cardiovascular events and death from any cause, but there was no clear effect on nonfatal myocardial infarction and researchers noted an adverse effect for nonfatal stroke.

Pioglitazone, but not rosiglitazone, associated with increased risk of bladder cancer

The results of this study pose the question of whether the increased likelihood of bladder cancer, which is rare, justifies withholding pioglitazone from adults with type 2 diabetes, according to an accompanying editorial.

Incretin-based drugs not associated with greater heart failure hospitalization risk than other drug combos in retrospective study

Researchers compared patients taking dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-like peptide 1 (GLP-1) analogues to those taking 2 or more oral antidiabetic drugs.

MKSAP quiz: History of diabetic ketoacidosis

This month's case asks readers to evaluate a 44-year-old man diagnosed with type 2 diabetes 6 months ago after being admitted to the hospital with diabetic ketoacidosis.

New warnings on medications containing saxagliptin, alogliptin

New warnings will be placed on saxagliptin and alogliptin about the potential risk of heart failure, particularly in patients with heart or kidney disease, the FDA announced on April 5.

Safety alert and advice on CT scanning in patients with insulin pumps

The presence of an insulin pump should not preclude an appropriate and medically indicated CT scan, the FDA said.

Spotlight on drug comparisons

Outcomes and costs of different classes of diabetes drugs were compared by studies published in the past month.